First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
J Greenhalgh, Angela Boland, Victoria Bates, Fabio Maria Vecchio, Y Dündar, Marty Chaplin, John A. Green
Abstract
Epidermal growth factor receptor (EGFR) mutation positive (M+) non-small cell lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non-squamous tumours. This subtype is more common in women than men, is less associated with smoking, but occurs at a younger age than sporadic tumours.
Topics & Concepts
MedicineInternal medicineOncologyLung cancerEpidermal growth factor receptorChemotherapyClinical trialProgression-free survivalCancerLung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and Treatment